CureZone   Log On   Join
Survival enhancement of patients with diffuse large B-cell lymphoma
 
marykudro Views: 89
Published: 5 months ago
 

Survival enhancement of patients with diffuse large B-cell lymphoma


The Ibrutinib drug is a kinase inhibitor that can do survival enhancement with diffuse large B-cell lymphoma observed in younger individuals. According to the findings published in Journal Cancer Cell, a new analysis by researchers at the USA’s National Cancer Institute conducted a phase-3 clinical trial.

Earlier patients with diffuse large B-cell lymphoma were treated with R-CHOP, but this therapy is not helpful for everyone with diffuse large B-cell lymphoma. 

Ibrutinib inhibits the function of Bruton tyrosine kinase, a protein that helps in the growth and survival of B cells. Cancerous cells of the ‘active B cell-like’ (ABC) subtype of diffuse large B-cell lymphoma require this protein to survive.

 
 

 
Printer-friendly version of this page Email this message to a friend
Alert Moderators
Report Spam or bad message  Alert Moderators on This GOOD Message

This Forum message belongs to a larger discussion thread. See the complete thread below. You can reply to this message!


 

Donate to CureZone


CureZone Newsletter is distributed in partnership with https://www.netatlantic.com


Contact Us - Advertise - Stats

Copyright 1999 - 2022  curezone.com

6.765 sec, (1)